RLAY Stock Analysis: Buy, Sell, or Hold?
RLAY - Relay Therapeutics, Inc. Common Stock
$18.83
-0.62 (-3.19%)
▼
5d:
+2.11%
30d:
+6.02%
90d:
+45.29%
BUY
MODERATE Confidence
Analysis Updated: Jul 31, 2026 12:00 AM ET
Earnings: Aug 06, 2026
3d
Smart Money Distribution
None View Scanner →
Strength: 5.6/10
Get Alerted When RLAY Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: RLAY shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: RLAY shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: RLAY is currently trading at $18.83, which is considered fair relative to its 30-day fair value range of $18.12 to $19.70.
Technical Outlook: Technically, RLAY is in a strong uptrend. Immediate support is located at $17.71, while resistance sits at $20.39. Short-term momentum is weak, with the stock down 3.2% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $26.08 (+38.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, RLAY is in a strong uptrend. Immediate support is located at $17.71, while resistance sits at $20.39. Short-term momentum is weak, with the stock down 3.2% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $26.08 (+38.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$18.12 -
$19.70
Company Quality Score
59/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
69.5%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.2%)
- BULLISH: Trading 38.5% below Wall St target ($26.08)
Trading Range Analysis
30-Day Trading Range
$18.12 -
$19.70
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$17.71
Resistance Level
$20.39
Current Trend
Strong Uptrend
Technical data as of
Jul 31, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-11.48
Wall Street Target
$26.08
(+38.5%)
Revenue Growth (YoY)
-60.9%
Share & Embed Analysis
Last updated: August 02, 2026 1:54 PM ET
Data refreshes hourly during market hours. Next update: 2:54 PM
Data refreshes hourly during market hours. Next update: 2:54 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is RLAY showing a specific setup today?
Insider Activity (6 Months)
0
Buys
2
Sells
Net
INSIDERS SELLING
Recent Transactions
Thomas Catinazzo
SELL
1800 shares
2026-04-09
Thomas Catinazzo
SELL
17717 shares
2026-04-07
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$416 | 53 HOLD |
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$386 | 43 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$557 | 49 HOLD |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$309 | 54 HOLD |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$86 | 47 HOLD |
